Although rare kidney diseases remain a significantly overlooked contributor to the global burden of CKD, things have begun to shift in recent years – in 2023, for example, an international panel ...

BMS and J&J's Librexia AF study is also comparing milvexian to Eliquis to see if it can prevent stroke and other clotting ...

Discover why Cytokinetics (CYTK) is a top BUY in precision cardiology. Learn about aficamten, its market potential, and ...

Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), a late-stage biopharmaceutical company ...

"We are executing our commercial strategy across multiple fronts, with each element reinforcing the others to drive momentum,” said Richard Lowenthal, Co-Founder, President and CEO of ARS Pharma. "Our ...

In the Phase III results presented and published today, olezarsen demonstrated rapid, substantial and significant reductions in triglycerides by up to 72% on top of standard of care and reduced the ...

This survey brief examines factors contributing to burnout among primary care physicians in 10 countries and strategies to ...

Risk stratification of patients with chest pain has traditionally focused on identifying obstructive coronary artery disease (CAD). Using this traditional approach, many symptomatic individuals are ...

Persistent liver injury halts the regenerative capacity of hepatocytes and activates mechanisms that result in the ...

Designing and running clinical trials to test the effectiveness and safety of a new drug is an extremely complex process. Doing this for rare diseases – defined in the United Kingdom as diseases ...